Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population

¹ Servicio de Neurología, Hospital Clínico San Carlos, 28040 Madrid, Spain
² Servicio de Neurología, Hospital Gregorio Marañón, 28007 Madrid, Spain
³ Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall D'hebron, 08035 Barcelona, Spain

^* To whom correspondence should be addressed.

	Abstract

Objectives To study the management of pregnancy in multiple sclerosis (MS) patients on immunomodulatory therapy (IMT) in routine clinical practice and to analyze pregnancy outcomes and the clinical course of MS around pregnancy. Methods Retrospective, multicentric study in Spain in MS patients receiving IMT before conception and followed for at least three months post-partum. Results A total of 1286 medical records were reviewed. Eighty-eight pregnancies were identified in 74 (6%) women, 66% of which were unexposed and 34% exposed pregnancies. In most cases, IMT was discontinued before conception and resumed shortly after delivery. Accidental exposure to IMT did not lead to higher rates of abortions (P = 0.76) or malformations. The relapse rate was decreased during pregnancy (0.31 versus 0.61 in the pre-pregnancy year) and increased after delivery (0.87 on month 3), returning to pre-conception values on month 12. The median EDSS score was not increased during the study. Conclusions Discontinuation of IMT before conception, and resumption shortly after delivery was the most frequent clinical practice procedure. Accidental exposure to IMT did not affect pregnancy outcomes or increased malformation rates. Pregnancy was associated with a reduced relapse rate. No factor was found to predict the risk of relapses during or after pregnancy. Multiple Sclerosis 2007; 00: 000-000. http://msj.sagepub.com

Key Words: accidental exposure; disability; immunomodulatory treatment; pregnancy; relapse rate

First published on July 10, 2007, doi:10.1177/1352458507077896

Multiple Sclerosis 2007;13:981.

A more recent version of this article appeared on September 1, 2007


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C Weber-Schoendorfer and C Schaefer Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study Multiple Sclerosis, September 1, 2009; 15(9): 1037 - 1042. [Abstract] [PDF]

				N Fernandez Liguori, D Klajn, L Acion, F Caceres, A Calle, A Carra, E Cristiano, N Deri, O Garcea, A Jaureguiberry, et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study) Multiple Sclerosis, May 1, 2009; 15(5): 555 - 562. [Abstract] [PDF]

				A. A. Argyriou and N. Makris Review Article: Multiple Sclerosis and Reproductive Risks in Women Reproductive Sciences, October 1, 2008; 15(8): 755 - 764. [Abstract] [PDF]